These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 1421831

  • 1. The management of hemophilia patients with inhibitors.
    Nilsson IM.
    Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U.
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract] [Full Text] [Related]

  • 3. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D, Rodgers GM.
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K, Schwarz P, Kunschak M.
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Inhibitors - cellular aspects and novel approaches for tolerance.
    Scott DW.
    Haemophilia; 2014 May; 20 Suppl 4(0 4):80-6. PubMed ID: 24762281
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
    Collins PW, Chalmers E, Hart DP, Liesner R, Rangarajan S, Talks K, Williams M, Hay CR, UK Haemophilia Centre Doctors.
    Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
    [No Abstract] [Full Text] [Related]

  • 12. A therapeutic alternative for haemophiliacs with inhibitors.
    Schulman S.
    Acta Paediatr; 1992 Jan; 81(6-7):564-5. PubMed ID: 1392376
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oral solutions.
    Dolgin E.
    Sci Am; 2015 Jan; 312(1):S12-3. PubMed ID: 25597119
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
    Astermark J, Morado M, Rocino A, van den Berg HM, von Depka M, Gringeri A, Mantovani L, Garrido RP, Schiavoni M, Villar A, Windyga J, EHTSB.
    Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
    [Abstract] [Full Text] [Related]

  • 17. Regimens of factor VIII administration--continuous infusion vs. bolus.
    Berntorp E.
    Haematologica; 2000 Oct; 85(10 Suppl):69-71; discussion 71-2. PubMed ID: 11187875
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M, Khair K, Hann I, Liesner R.
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [Abstract] [Full Text] [Related]

  • 20. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
    Biss TT, Chan AK, Blanchette VS, Iwenofu LN, McLimont M, Carcao MD, Association of Hemophilia Clinic Directors of Canada (AHCDC), Canadian Association of Nurses in Hemophilia Care (CANHC).
    Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.